Business Context and Reporting Period
This Form 8-K Current Report was filed by Fluidigm Corporation (Note: The request metadata lists "Standard BioTools Inc.", but the filing text identifies the registrant as Fluidigm Corporation) on December 15, 2020. The report discloses corporate governance changes, specifically the appointment of a new director and the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director compensation and appointment details rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Appointment: Ana K. Stankovic, MD, PhD, MSPH, was appointed as a Class II director to fill the new vacancy.
- Term: Dr. Stankovic's term expires at the 2021 annual meeting of stockholders.
Compensation and Governance Details
Dr. Stankovic's compensation package includes:
- Cash Retainer: Base annual retainer of $40,000 for non-employee directors.
- Committee Fees: Additional annual cash compensation for committee service (Audit: $10,000; Compensation: $7,000; Nominating and Corporate Governance: $5,000).
- Equity Awards: Granted an option to purchase common stock and a restricted stock unit award, each with a grant date value of $55,000.
- Vesting Schedule: Initial equity awards vest in four equal yearly installments beginning on the first anniversary of the grant date, contingent on continued service.
- Indemnification: Dr. Stankovic entered into the Company's standard form of indemnification agreement.
Investor Verification Checklist
- Verify the current Board composition and the specific committee assignments for Dr. Stankovic to determine total potential cash compensation.
- Review the press release (Exhibit 99.1) for additional context on Dr. Stankovic's background and qualifications.
- Confirm the total number of outstanding equity awards granted to the Board under the 2011 Equity Incentive Plan.
- Note the discrepancy between the request metadata ("Standard BioTools Inc.") and the filing registrant ("Fluidigm Corporation") to ensure the correct entity is being analyzed.